All In Biotech

Drug Trial Radar · NCT07449390

Drug-drug Interaction Trial of AP31969 and Carbamazepine or Itraconazole

Open-label, 2-Part, Fixed-sequence, Crossover Trial Design to Determine the Effect of a Strong CYP3A4 Inducer (Carbamazepine) And a Strong CYP3A4 Inhibitor (Itraconazole) on the Pharmacokinetics of a Single Oral Dose of AP31969 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: May 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

28

Actual

Start

Apr 1, 2026

Primary completion

May 9, 2026

Study completion May 16, 2026

Sponsor

Lead sponsor
Acesion PharmaIndustry
Sponsor type
Industry
First posted
Mar 4, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Crossover
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The primary objective of the trial is to assess the effect of multiple doses of the cytochrome P450 (CYP3A4) enzyme inducer carbamazepine (Part A) or the CYP3A4 inhibitor itraconazole (Part B) on the single-dose pharmacokinetics (PK) of AP31969 in healthy participants.

Conditions

  • Healthy Participants

Interventions

  • AP31969Drug

    Oral tablets.

  • CarbamazepineDrug

    Oral capsules.

  • ItraconazoleDrug

    Oral tablets.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of AP31969 When Administered Alone and With CarbamazepineTime frame: AP31969 alone: predose, and at 0.5 to 72 hours postdose on Day 1 and AP31969 in combination: predose, and at 0.5 to 72 hours postdose on Day 15; Carbamazepine alone: predose on Day 15 and morning on Day 18
  2. Part B: Cmax of AP31969 When Administered Alone and With ItraconazoleTime frame: AP31969 alone: predose, and at 0.5 to 72 hours postdose on Day 1, and AP31969 in combination: predose and at 0.5 to 144 hours postdose on Day 15; Itraconazole alone: predose on Day 7 and morning on Day 13
  3. Part A: Area Under the Plasma Concentration-time Curve (AUC) from Time 0 to Time of Last Quantifiable Concentration (AUC0-last) of AP31969 When Administered Alone and With CarbamazepineTime frame: AP31969 alone: predose, and at 0.5 to 72 hours postdose on Day 1 and AP31969 in combination: predose, and at 0.5 to 72 hours postdose on Day 15; Carbamazepine alone: predose on Day 15 and morning on Day 18
  4. Part B: AUC0-last of AP31969 When Administered Alone and With ItraconazoleTime frame: AP31969 alone: predose, and at 0.5 to 72 hours postdose on Day 1, and AP31969 in combination: predose and at 0.5 to 144 hours postdose on Day 15; Itraconazole alone: predose on Day 7 and morning on Day 13
  5. Part A: AUC from Time 0 to Infinity (AUC0-inf) of AP31969 When Administered Alone and With CarbamazepineTime frame: AP31969 alone: predose, and at 0.5 to 72 hours postdose on Day 1 and AP31969 in combination: predose, and at 0.5 to 72 hours postdose on Day 15; Carbamazepine alone: predose on Day 15 and morning on Day 18
  6. Part B: AUC0-inf of AP31969 When Administered Alone and With ItraconazoleTime frame: AP31969 alone: predose, and at 0.5 to 72 hours postdose on Day 1, and AP31969 in combination: predose and at 0.5 to 144 hours postdose on Day 15; Itraconazole alone: predose on Day 7 and morning on Day 13

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • ICON Early Phase Services, LLC

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.